trial
as of 2026-07-01Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
NCTId NCT02717195
at a glance
Phase 3 · Completed
Enrollment 1,098 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2018-08-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
1,098 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-04
Primary completion
2018-08-30
Eligibility
ALL · 18 Years
Interventions & indications
Indications
Sponsors
H. Lundbeck A/SLead Sponsor
Sites
147 total
Bellflower, United StatesCerritos, United StatesCosta Mesa, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesNational City, United StatesOceanside, United StatesOceanside, United StatesOrange, United StatesOrange, United StatesSan Bernardino, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
1,098
Phase
PHASE3
Primary Completion Date
2018-08-30
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
indication
indication
indication